Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment-resistant depression
2005-001217-17Phase 4Active
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in treatment-resistant depression (TRD), major depressive disorder (MDD) and bipolar disorder (BD) comparing Venlafaxine + lamotrigine, Venlafaxine + quetiapine and Venlafaxine + placebo (3 arms). Primary endpoints: Change in depressive symptom severity (HDRS) and Change in depressive symptom severity (MADRS). Started Jun 2005; status: active.
02
Drugs
venlafaxinelamotriginequetiapine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2005-001217-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001217-17.